Inhibitory effects of resistin-13-peptide on the proliferation, adhesion, and invasion of MDA-MB-231 in human breast carcinoma cells

Endocrine-Related Cancer

Volumn 14, Issue 4, 2007, Pages 1063-1071

  Pan, Bing ^a   Zhao, Ming Hui ^a   Chen, Zhong ^a   Lu, Lu ^a   Wang, Yan ^a   Shi, Da Wei ^a   Han, Pei Zhen ^a  

^a INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GELATINASE A; GELATINASE B; RESISTIN; RESISTIN 13; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL ADHESION; CELL GROWTH; CELL LINE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TUMOR GROWTH; UPREGULATION; XENOGRAFT; ZYMOGRAPHY;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; RESISTIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 39149116023     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01304     Document Type: Article

References (27)

1. Aimes RT & Quigley JP 1995 Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. Journal of Biological Chemistry 270 5872-5876.
2. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ & Chapman MJ 2004 Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clinical Chemistry and Laboratory Medicine 42 121-131.
3. Bergers G, Javaherian K, Lo K, Folkman J & Hanahan D 1999 Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 808-812.
4. Cottam DW, Rennie IG, Woods K, Parsons MA, Bunning RA & Rees RC 1992 Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Investigative Ophthalmology and Visual Science 33 1923-1927.
5. Coussens ML, Fingleton B & Matrisian LM 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 2387-2392.
6. Curran S & Murray GI 2000 Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. European Journal of Cancer 36 1621-1630.
7. Dewhurst LO, Gee JW, Rennie IG & MacNeil S 1997 Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. British Journal of Cancer 75 860-868.
8. Duffy MJ, Maguire TM, Hill A, McDermott E & O'Hiffins N 2000 Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Research 2 252-257.
9. Fenton JI, Hord NG, Lavigne JA, Perkins SN & Hursting SD 2005 Leptin, insulin-like growth factor-1, and insulin-like growth factor-2 are mitogens in ApcMin/+ but not Apc+/+ colonic epithelial cell lines. Cancer Epidemiology, Biomarkers and Prevention 14 1646-1652.
10. Jiang MC, Liao CF & Lee PH 2001 Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochemical and Biophysical Research Communications 282 671-677.
11. John A & Tuszynski G 2001 The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathology and Oncology Research 7 14-23.
12. Kleiner DE & Stetler-Stevenson WG 1993 Structural biochemistry and activation of matrix metalloproteinases. Current Opinion in Cell Biology 5 891-897.
13. Koemer A, Kratzsch J & Kiess W 2005 Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Practice & Research. Clinical Endocrinology and Metabolism 19 525-546.
14. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 680-685.
15. Liotta LA 1986 Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Research 46 1-7.
16. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH & Kumar S 2002a Resistin, central obesity, and type 2 diabetes. Lancet 359 46-47.
17. McTernan PG, Mcternan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH & Kumar S 2002b Increased resistin gene and protein expression in humanabdominal adipose tissue. Journal of Clinical Endocrinology and Metabolism 87 2407.
18. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J & Clark I 2002 Matrix metalloproteinases in arthritic disease. Arthritis Research 4 S39-S49.
19. Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moritra J, Varticovski L et al. 2006 Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Research 66 5469-5476.
20. Rajala MW & Scherer PE 2003 Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 3765-3773.
21. Seiki M 2003 Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Letters 194 1-11.
22. Di Simone N, Di Nicuolo F, Sanguinetti M, Castellani R, D'Asta M, Caforio L & Caruso A 2006 Resistin regulates human choriocarcinoma cell invasive behaviour and endothelial cell angiogenic processes. Journal of Endocrinology 189 691-699.
23. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS & Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409 307-312.
24. Sternlicht MD & Werb Z 2001 How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 17 463-516.
25. Sugiyama T & Sadzuka Y 1999 Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Clinical Cancer Research 5 413-416.
26. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF & Adam HO 2001 A prospective study of obesity and cancer risk (Sweden). Cancer Causes and Control 12 13-21.
27. Zhao M-H, Wang Y, Zhang C-M, Wang D-Z & Han P-Z 2005 Preparation of anti-resistin peptide antibody. Biomedical Engineering and Clinical Medicine 9 163-165.